Home
Contact
Sitemap
Santen Worldwide
HOME
About AVS
News
Products
Careers
Compliance
About Santen
News
News
Latest News!
2012
Nov 1 2012
Santen Announces Financial Result for the Second Quarter ended September 30, 2012
Sep 28 2012
Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Sep 25 2012
Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs
Sep 25 2012
Notice on the Establishment of a New Sales and Marketing Company in China
Aug 1 2012
Santen Announces Financial Result for the First Quarter ended June 30, 2012
June 25 2012
FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS
May 8 2012
Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)
May 8 2012
Santen Announces Financial Results for the Year ended March 31, 2012
Mar 9 2012
Notice of the appointment of Corporate Officers
Mar 1 2012
Santen to Launch Sante Medical Guard OTC Eye Drop
Feb 14 2012
FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication
Feb 7 2012
Santen Announces Financial Result for the Third Quarter ended December 31, 2011
Feb 7 2012
Notice on the Establishment of Holding Company in Europe
Jan 24, 2012
Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA
2011
Nov 1, 2011
Santen Announces Financial Result for the Second Quarter ended September 30, 2011
Oct 24, 2011
AVS celebrates 10 years of being a Santen Company!
Oct 21, 2011
Eternity Uni: W-60 6mm single-piece intraocular lens gets PMDA approval
Oct 14, 2011
Ube and Santen Announce License and Collaboration Agreement for EP2 Agonist
Oct 12, 2011
Santen Pharmaceutical Co., Ltd. completes the acquisition of a controlling interest in Novagali Pharma S.A.
Aug 2, 2011
Notice on the Establishment of Subsidiary in India
Aug 2, 2011
Santen Announces Financial Result for the First Quarter ended June 30, 2011
Jun 2, 2011
Santen Launches Broad-spectrum Antibacterial Ophthalmic Solution Cravit Ophthalmic Solution 1.5%
May 10, 2011
Announcement of the Year-end Dividends
Apr 14, 2011
Santen Inc. Head Office Relocation
Mar 17, 2011
Effect of the Tohoku-Kanto Earthquake on Santen
Mar 15, 2011
Notice of Donation with regards to the Tohoku-Kanto Earthquake
Feb 14, 2011
Notice Concerning Changes in Status of Major Shareholders After Disposal of Treasury Stock Through Third-Party Allotment
Feb 8, 2011
Santen Announces Financial Result for the Third Quarter ended December 31, 2010
Feb 3, 2011
AVS and Santen support
SummitforCure!
and donate to
Himalayan Cataract Project
to cure world blindness. See
SummitforCure!.
Jan 1, 2011
AVS/Santen flags fly high on top of Africa - Uhuru Peak (5,895 meters or 19,340 feet) on Mt. Kilimanjaro, an inactive stratovolcanic peak in Tanzania.
2010
Dec 13, 2010
Santen Launches DIQUAS Ophthalmic Solution 3% for Dry Eye Treatment in Japan
Nov 2, 2010
Santen Announces Financial Result for the Second Quarter ended September 30, 2010
Sep 7, 2010
The US patent for "Non- or reduced glistenings intraocular lens and method of manufacturing same" was granted to AVS on Sep 7 2010
See a copy of the patent here:
US patent number 7789509
Aug 3, 2010
Santen Announces Financial Result for the First Quarter ended June 30, 2010
June 11, 2010
Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug
May 11, 2010
Santen Announces Financial Results for the Year ended March 31, 2009
Apr 16, 2010
Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan
Feb 2, 2010
Santen Announces Financial Result for the Third Quarter ended December 31, 2009
2009
Aug 25, 2009
Eternity Natural IOL, a blue-light blocking version of Eternity intraocular lens receives approval from PMDA for marketing in Japan.
May 12, 2009
Santen Announces Financial Results for the Year ended March 31, 2009
Apr 15, 2009
Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost, Treatment for Glaucoma and Ocular Hypertension
Mar 10, 2009
Consumer Information on: Xact® Soft Acrylic UV Light-Absorbing Posterior Chamber Intraocular Lens - P080021 available on FDA CDRH Website
Mar 3, 2009
Santen Pharmaceutical Co., Ltd. (Santen) licenses development, manufacturing and marketing rights of its AVS Xact® hydrophobic acrylic lens material to Bausch & Lomb Inc.(B&L)
Feb 2, 2009
FDA Announces Pre-market Approval of Xact® Foldable Hydrophobic Acrylic Ultraviolet Light-Absorbing Posterior Chamber Intraocular Lens (IOL) - Glistening-Free IOL
2008
Nov 5, 2008
Santen Announces Financial Result for the Second Quarter ended September 30, 2008
Oct 17, 2008
Santen Announces Approval of TAPROS™ for Glaucoma and Ocular Hypertension Treatment in Japan
Oct 3, 2008
Santen to Launch Sante 40i OTC Eye Drop
Go Tarheels!
